|
December 6, 2005 Categories: Blogroll Posted by admin
Cordis Corporation, a Johnson & Johnson company, today announced that the U.S. Food and Drug Administration (FDA) has approved a condition of use for the CYPHER(R) Sirolimus-eluting Coronary Stent, allowing patients receiving the stent to immediately undergo Magnetic Resonance Imaging (MRI) following implantation. Approval was granted after laboratory studies demonstrated the CYPHER(R) Stent is MRI-safe.
Full news
|
|
